ORGANOGENESIS HOLDINGS INC (ORGO) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:ORGO • US68621F1021

3.84 USD
+0.01 (+0.26%)
At close: Feb 10, 2026
3.91 USD
+0.07 (+1.82%)
After Hours: 2/10/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

Taking everything into account, ORGO scores 5 out of 10 in our fundamental rating. ORGO was compared to 523 industry peers in the Biotechnology industry. ORGO has an average financial health and profitability rating. ORGO is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • ORGO had positive earnings in the past year.
  • In the past year ORGO has reported a negative cash flow from operations.
  • Of the past 5 years ORGO 4 years were profitable.
  • In the past 5 years ORGO always reported a positive cash flow from operatings.
ORGO Yearly Net Income VS EBIT VS OCF VS FCFORGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

  • ORGO has a better Return On Assets (-2.63%) than 87.38% of its industry peers.
  • ORGO's Return On Equity of -3.47% is amongst the best of the industry. ORGO outperforms 89.10% of its industry peers.
  • The Return On Invested Capital of ORGO (0.16%) is better than 88.72% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for ORGO is significantly below the industry average of 18.27%.
Industry RankSector Rank
ROA -2.63%
ROE -3.47%
ROIC 0.16%
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ORGO Yearly ROA, ROE, ROICORGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50 -100

1.3 Margins

  • ORGO has a Operating Margin of 0.18%. This is amongst the best in the industry. ORGO outperforms 88.72% of its industry peers.
  • In the last couple of years the Operating Margin of ORGO has declined.
  • ORGO has a better Gross Margin (74.49%) than 83.37% of its industry peers.
  • ORGO's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 0.18%
PM (TTM) N/A
GM 74.49%
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
ORGO Yearly Profit, Operating, Gross MarginsORGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • ORGO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, ORGO has less shares outstanding
  • The number of shares outstanding for ORGO has been increased compared to 5 years ago.
  • The debt/assets ratio for ORGO has been reduced compared to a year ago.
ORGO Yearly Shares OutstandingORGO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ORGO Yearly Total Debt VS Total AssetsORGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 3.64 indicates that ORGO is not in any danger for bankruptcy at the moment.
  • With a decent Altman-Z score value of 3.64, ORGO is doing good in the industry, outperforming 69.98% of the companies in the same industry.
  • ORGO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of ORGO (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 3.64
ROIC/WACC0.01
WACC12.78%
ORGO Yearly LT Debt VS Equity VS FCFORGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • ORGO has a Current Ratio of 3.32. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • ORGO has a Current ratio of 3.32. This is in the lower half of the industry: ORGO underperforms 60.04% of its industry peers.
  • ORGO has a Quick Ratio of 2.88. This indicates that ORGO is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.88, ORGO is not doing good in the industry: 63.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 3.32
Quick Ratio 2.88
ORGO Yearly Current Assets VS Current LiabilitesORGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • The earnings per share for ORGO have decreased strongly by -90.91% in the last year.
  • ORGO shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -37.90% yearly.
  • ORGO shows a small growth in Revenue. In the last year, the Revenue has grown by 2.24%.
  • Measured over the past years, ORGO shows a quite strong growth in Revenue. The Revenue has been growing by 13.05% on average per year.
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%

3.2 Future

  • The Earnings Per Share is expected to grow by 29.27% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, ORGO will show a quite strong growth in Revenue. The Revenue will grow by 8.70% on average per year.
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ORGO Yearly Revenue VS EstimatesORGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
ORGO Yearly EPS VS EstimatesORGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 384.00, which means the current valuation is very expensive for ORGO.
  • Based on the Price/Earnings ratio, ORGO is valued cheaper than 88.72% of the companies in the same industry.
  • ORGO is valuated expensively when we compare the Price/Earnings ratio to 28.03, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 25.96, the valuation of ORGO can be described as expensive.
  • Based on the Price/Forward Earnings ratio, ORGO is valued cheaply inside the industry as 92.35% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 27.97. ORGO is around the same levels.
Industry RankSector Rank
PE 384
Fwd PE 25.96
ORGO Price Earnings VS Forward Price EarningsORGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ORGO indicates a rather cheap valuation: ORGO is cheaper than 93.50% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 22.42
ORGO Per share dataORGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • ORGO has a very decent profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as ORGO's earnings are expected to grow with 29.27% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.73%
EPS Next 3Y29.27%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ORGO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ORGANOGENESIS HOLDINGS INC

NASDAQ:ORGO (2/10/2026, 8:00:02 PM)

After market: 3.91 +0.07 (+1.82%)

3.84

+0.01 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)02-26
Inst Owners54.62%
Inst Owner Change0.03%
Ins Owners31.34%
Ins Owner Change-0.43%
Market Cap487.33M
Revenue(TTM)465.22M
Net Income(TTM)-13.39M
Analysts85
Price Target8.67 (125.78%)
Short Float %19.11%
Short Ratio10.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)47.19%
Min EPS beat(2)-73%
Max EPS beat(2)167.38%
EPS beat(4)2
Avg EPS beat(4)147.99%
Min EPS beat(4)-73%
Max EPS beat(4)570.59%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)3.03%
Min Revenue beat(2)-4.23%
Max Revenue beat(2)10.3%
Revenue beat(4)2
Avg Revenue beat(4)3.25%
Min Revenue beat(4)-6.36%
Max Revenue beat(4)13.3%
Revenue beat(8)5
Avg Revenue beat(8)2.23%
Revenue beat(12)6
Avg Revenue beat(12)1.36%
Revenue beat(16)7
Avg Revenue beat(16)0.62%
PT rev (1m)0%
PT rev (3m)6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)35.48%
EPS NY rev (1m)0%
EPS NY rev (3m)216.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)3.66%
Revenue NY rev (1m)0%
Revenue NY rev (3m)5.49%
Valuation
Industry RankSector Rank
PE 384
Fwd PE 25.96
P/S 1.05
P/FCF N/A
P/OCF N/A
P/B 1.26
P/tB 1.4
EV/EBITDA 22.42
EPS(TTM)0.01
EY0.26%
EPS(NY)0.15
Fwd EY3.85%
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS3.67
BVpS3.04
TBVpS2.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0.83
Profitability
Industry RankSector Rank
ROA -2.63%
ROE -3.47%
ROCE 0.2%
ROIC 0.16%
ROICexc 0.19%
ROICexgc 0.21%
OM 0.18%
PM (TTM) N/A
GM 74.49%
FCFM N/A
ROA(3y)1.45%
ROA(5y)6.32%
ROE(3y)2.46%
ROE(5y)11.67%
ROIC(3y)3.79%
ROIC(5y)7.32%
ROICexc(3y)5.35%
ROICexc(5y)10.84%
ROICexgc(3y)6.4%
ROICexgc(5y)14.92%
ROCE(3y)4.79%
ROCE(5y)9.27%
ROICexgc growth 3Y-38.4%
ROICexgc growth 5YN/A
ROICexc growth 3Y-36.47%
ROICexc growth 5YN/A
OM growth 3Y-34.07%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.17%
GM growth 5Y1.4%
F-Score2
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA 0.11
Cap/Depr 70.73%
Cap/Sales 2.76%
Interest Coverage 0.99
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.32
Quick Ratio 2.88
Altman-Z 3.64
F-Score2
WACC12.78%
ROIC/WACC0.01
Cap/Depr(3y)177.81%
Cap/Depr(5y)208.05%
Cap/Sales(3y)5.07%
Cap/Sales(5y)5.42%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-90.91%
EPS 3Y-37.9%
EPS 5YN/A
EPS Q2Q%66.67%
EPS Next Y-58%
EPS Next 2Y-6.73%
EPS Next 3Y29.27%
EPS Next 5YN/A
Revenue 1Y (TTM)2.24%
Revenue growth 3Y0.98%
Revenue growth 5Y13.05%
Sales Q2Q%30.98%
Revenue Next Year9.76%
Revenue Next 2Y8.03%
Revenue Next 3Y8.7%
Revenue Next 5YN/A
EBIT growth 1Y-91.44%
EBIT growth 3Y-33.42%
EBIT growth 5YN/A
EBIT Next Year563.55%
EBIT Next 3Y112.83%
EBIT Next 5YN/A
FCF growth 1Y-1334.78%
FCF growth 3Y-48.6%
FCF growth 5YN/A
OCF growth 1Y-238.05%
OCF growth 3Y-38.8%
OCF growth 5YN/A

ORGANOGENESIS HOLDINGS INC / ORGO FAQ

Can you provide the ChartMill fundamental rating for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a fundamental rating of 5 / 10 to ORGO.


Can you provide the valuation status for ORGANOGENESIS HOLDINGS INC?

ChartMill assigns a valuation rating of 4 / 10 to ORGANOGENESIS HOLDINGS INC (ORGO). This can be considered as Fairly Valued.


What is the profitability of ORGO stock?

ORGANOGENESIS HOLDINGS INC (ORGO) has a profitability rating of 6 / 10.


What is the financial health of ORGANOGENESIS HOLDINGS INC (ORGO) stock?

The financial health rating of ORGANOGENESIS HOLDINGS INC (ORGO) is 5 / 10.